The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A First in Human, Dose Escalation Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors
Official Title: A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Study ID: NCT03518554
Brief Summary: This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
HealthONE Clinic Services Oncology-Hematology, Denver, Colorado, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Name: Jacobio Pharmaceuticals
Affiliation: Jacobio Pharmaceuticals Co., Ltd.
Role: STUDY_DIRECTOR